Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Flares Rare After COVID Vaccination

Catherine Kolonko  |  March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases.

An argument for reducing or discontinuing methotrexate and other immune-suppressing anti-rheumatic drugs at the time of a SARS-CoV-2 vaccination is that it may improve the ability to trigger the humoral antibody response to the vaccine. On the other hand, the clinical significance of such an improved response is yet to be determined, and withholding medications carries the potential risk of exacerbating the disease, noted the study’s author, Pedro Machado, PhD, a professor of rheumatology and neuromuscular diseases at University College London Queen Square Institute of Neurology, in an email interview.

Pedro Machado, PhD

Pedro Machado, PhD

Machado et al. investigated the frequency and factors associated with IRMD flares in patients who were vaccinated against SARS-CoV-2.1

Results from the large, international study showed flares were uncommon following SARS-CoV-2 vaccination among patients with IRMD, a finding that may advance treatment approaches for patients before and after vaccination against COVID-19, say the study’s authors.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Some patients may be concerned the COVID-19 vaccine may trigger flares, or those who are immunosuppressed may worry the vaccine will give them the infection it is meant to prevent. The study’s authors say this research will help patients and their rheumatologists decide together the best approach to management of IRMD with respect to vaccination.

“Our findings confirm that while flares in IRMDs following SARS-CoV-2 vaccination are possible, they are infrequently observed,” says Dr. Machado.

“It’s reassuring data about COVID vaccinations in systemic autoimmune rheumatic diseases,” says Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS, physician editor of The Rheumatologist.

Existing Guidance

Recommendations from EULAR and the ACR differ somewhat on how or whether to use anti-rheumatic drugs at or near the time a patient with IRMD receives a COVID-19 vaccine. The ACR recommends withholding methotrexate and certain other drugs in patients with controlled disease; however, EULAR does not recommend reducing or halting anti-rheumatic drugs, with the exception of rituximab.

Jeffrey Curtis, MD, MS, MPH

Jeffrey Curtis, MD, MS, MPH

The ACR guidelines and guidance are intended to be adaptable, living documents that get updated as evidence evolves, notes Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.2 Therefore, the guidance on whether to hold or delay immunosuppressive medications in relation to timing a COVID-19 vaccine can change in the face of new evidence, and more recent guidance by the Centers for Disease Control & Prevention may supersede earlier guidance, Dr. Curtis said in an email interview.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceGuidelinesResearch ReviewsResearch Rheum Tagged with:COVID-19flarevaccination

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Anze Furlan / SHUTTERSTOCK.COM

    How Immunosuppression May Affect COVID-19 Vaccine Response

    June 13, 2021

    Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

    COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall

    August 20, 2021

    At a recent ACR town hall, panelists described immune responses and side effects of COVID-19 vaccination in patients with rheumatic disease, along with ways to leverage monoclonal antibody treatments, especially in light of virus variants.

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences